Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747348 | 0.96 | TSHR (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11748204 | 0.81 | TSHR (0.32) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL8433121 | 0.80 | TSHR (0.33) | TSHR | |
| SCHEMBL8455989 | 0.77 | CHRNB2 (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL14759451 | 0.77 | CHRNB2 (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3822564 | 0.76 | MAPT (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9728294 | 0.76 | KMT2A (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL10369020 | 0.76 | MAPT (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL6461670 | 0.76 | MAPT (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL26183 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302487-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2012-11-29 | — | — | US | claimed |
| EP-2494024-A1 | COMPOSITE | Revolymer Limited (GB) | 2012-09-05 | — | — | EP | claimed |
| WO-2011051681-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2011-05-05 | — | — | WO | claimed |
| US-20140171327-A1 | NOVEL COMPOSITE | REVOLYMER (U.K.) LIMITED (GB) | 2014-06-19 | — | — | US | disclosed |
| US-20120302487-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| EP-2494024-A1 | COMPOSITE | Revolymer Limited (GB) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051681-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171327-A1 | NOVEL COMPOSITE | PUF60, C5, VCL | TSHR 4817/4885CHRM2 3026/4885CHRM4 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.